HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

[Acquired factor V inhibitor: etiology, bleeding risk and therapeutic management with regard to three cases]

AbstractINTRODUCTION: Acquired factor V inhibitor is rare and clinical symptoms are quite variable. Bleeding is the leading symptom but some patients are asymptomatic. Several diseases or conditions are associated with factor V inhibitors. Various treatments have been attempted but randomized or prospective trials are not available. EXEGESIS: Here we report three cases of acquired factor V inhibitor. These reports highlight the clinical variability of this disorder. Pathogenesis and therapy with reference to the literature are discussed. CONCLUSION: Factor V inhibitors are rare and associated to several diseases or conditions. Pathogenesis is still unclear except in patients exposed to bovine thrombin. The majority of the cases developed after surgery. In a few cases there is an association to a malignant or autoimmune disease. Plasmapheresis and platelet transfusions might be the best treatment in case of severe bleeding. High-dose intravenous immunoglobulin infusions have been used successfully in some cases and we report here their efficacy in two cases.
AuthorsN Schleinitz, V Veit, D Chouquet, V Seux, D Arnoux, D Mokart, B Lelong, M C Alessi, G Kaplanski, J R Harlé (Affiliation: Service de médecine interne, hôpital de la Conception, 13385 Marseille, France. nschleinitz at mail.ap-hm.fr)
JournalLa Revue de médecine interne / fondée ... par la Société nationale francaise de médecine interne (Rev Med Interne) Vol. 22 Issue 11 Pg. 1119-23 (Nov 2001) ISSN: 0248-8663 [Print] France
Vernacular TitleAnticoagulant acquis antifacteur V: nosologie, risque hémorragique et prise en charge thérapeutique à propos de trois observations.
PMID11817124 (Publication Type: Case Reports, English Abstract, Journal Article)
Chemical References
  • Factor V
Topics
  • Aged
  • Blood Coagulation Disorders (etiology)
  • Factor V (antagonists & inhibitors)
  • Female
  • Hemorrhage (etiology, prevention & control)
  • Humans
  • Male
  • Middle Aged
  • Postoperative Complications
  • Risk Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Research Interface PRO additionally includes drill-down to evidence, articles by author, export to Excel, FDA Link and mobile subscription:
1 year subscription, $45.00 USD